JP2023535956A5 - - Google Patents

Info

Publication number
JP2023535956A5
JP2023535956A5 JP2023505687A JP2023505687A JP2023535956A5 JP 2023535956 A5 JP2023535956 A5 JP 2023535956A5 JP 2023505687 A JP2023505687 A JP 2023505687A JP 2023505687 A JP2023505687 A JP 2023505687A JP 2023535956 A5 JP2023535956 A5 JP 2023535956A5
Authority
JP
Japan
Prior art keywords
sequence
vector according
nucleic acid
promoter
aav vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/043582 external-priority patent/WO2022026632A2/en
Publication of JP2023535956A publication Critical patent/JP2023535956A/ja
Publication of JP2023535956A5 publication Critical patent/JP2023535956A5/ja
Pending legal-status Critical Current

Links

JP2023505687A 2020-07-29 2021-07-28 改善されたx連鎖性網膜分離症のaav媒介療法 Pending JP2023535956A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058437P 2020-07-29 2020-07-29
US63/058,437 2020-07-29
PCT/US2021/043582 WO2022026632A2 (en) 2020-07-29 2021-07-28 Improved aav-mediated x-linked retinoschisis therapies

Publications (2)

Publication Number Publication Date
JP2023535956A JP2023535956A (ja) 2023-08-22
JP2023535956A5 true JP2023535956A5 (cg-RX-API-DMAC7.html) 2024-07-05

Family

ID=77726514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505687A Pending JP2023535956A (ja) 2020-07-29 2021-07-28 改善されたx連鎖性網膜分離症のaav媒介療法

Country Status (8)

Country Link
US (1) US20230265455A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188450A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023535956A (cg-RX-API-DMAC7.html)
CN (1) CN116568338A (cg-RX-API-DMAC7.html)
AU (1) AU2021319065A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190214A1 (cg-RX-API-DMAC7.html)
IL (1) IL299927A (cg-RX-API-DMAC7.html)
WO (1) WO2022026632A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154535A1 (en) 2019-01-23 2020-07-30 University Of Florida Research Foundation, Incorporated Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
US20240124893A1 (en) * 2021-11-03 2024-04-18 Teamedon International, Inc. Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
CA3255242A1 (en) * 2022-03-30 2023-10-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated viral vectors for the delivery of nucleic acids across retinal regions
EP4511496A4 (en) * 2022-04-18 2026-06-24 Abeona Therapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT OPTIC ATROPHY AND X-RELATED RETINOSCHISISIS
CN116970648A (zh) * 2022-04-24 2023-10-31 上海朗昇生物科技有限公司 新型aav衣壳改造株及其用途
CN114848850B (zh) * 2022-04-28 2023-12-15 武汉中眸生物科技有限责任公司 Rs1基因在制备xlrs治疗剂中的应用及治疗剂
CN118359687A (zh) * 2023-01-18 2024-07-19 上海朗昇生物科技有限公司 一种新衣壳蛋白变体以及其用途
EP4704920A1 (en) * 2023-05-04 2026-03-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment
WO2025022144A1 (en) * 2023-07-26 2025-01-30 Sorbonne Universite Chimeric promoter for targeted expression in aii amacrine cells
WO2025091025A1 (en) * 2023-10-26 2025-05-01 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders relating to sirt1
WO2025113432A1 (zh) * 2023-11-27 2025-06-05 北京因诺惟康医药科技有限公司 一种用于治疗x染色体连锁视网膜劈裂症的基因药物
TW202605144A (zh) * 2024-05-02 2026-02-01 美商艾維斯塔醫療公司 用於將治療性核酸遞送至視網膜細胞之腺相關病毒載體

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
CN105120901A (zh) * 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
WO2014124282A1 (en) * 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies
AU2014216160B2 (en) * 2013-02-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV8 retinoschisin expression vector for treating X-linked retinoschisis
JP2016517278A (ja) * 2013-03-15 2016-06-16 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
EP3113787B1 (en) * 2014-03-04 2019-12-04 University of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
PT3628334T (pt) * 2014-03-21 2023-09-26 Genzyme Corp Terapia genética para retinopatia pigmentar
WO2016149664A1 (en) 2015-03-18 2016-09-22 University Of Florida Research Foundation, Inc. Methods and compositions for restoration of cone function in bcm
WO2017066579A1 (en) * 2015-10-14 2017-04-20 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2017070491A1 (en) * 2015-10-23 2017-04-27 Applied Genetic Technologies Corporation Ophthalmic formulations
EP3585883A4 (en) 2017-02-21 2021-04-14 University of Florida Research Foundation, Incorporated MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019144077A1 (en) * 2018-01-22 2019-07-25 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions for treating genetically linked diseases of the eye
US12605466B2 (en) * 2019-03-04 2026-04-21 University Of Florida Research Foundation, Incorporated Enhanced human opsin promoter for rod specific expression
WO2021102104A1 (en) * 2019-11-20 2021-05-27 University Of Massachusetts Aav-based delivery of thymine kinase 2

Similar Documents

Publication Publication Date Title
JP2023088902A5 (cg-RX-API-DMAC7.html)
EP3448437B1 (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
AU2025271096A1 (en) A modified mGluR6 promoter and methods of use
RU2765826C2 (ru) Векторная система на основе аденоассоциированного вируса
JP2024523707A5 (cg-RX-API-DMAC7.html)
CN110191954B (zh) 用于治疗涉及rdh12的病症和疾病的方法和组合物
JP2018512125A (ja) 多重ベクターシステム及びその使用
JP2022529782A5 (cg-RX-API-DMAC7.html)
JP2020512822A5 (cg-RX-API-DMAC7.html)
CN103562396A (zh) 用于无脉络膜的基因疗法的aav载体
WO2017070491A1 (en) Ophthalmic formulations
JP2019502378A5 (cg-RX-API-DMAC7.html)
JP2019524090A5 (cg-RX-API-DMAC7.html)
RU2018125468A (ru) Генная терапия офтальмологических нарушений
JP2021500922A5 (cg-RX-API-DMAC7.html)
AU2023274191B2 (en) Codon-Optimised Complement Factor I
CN121575014A (zh) 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗
JP2022539156A (ja) ヒアルロン酸を用いた眼組織へのaav媒介形質導入の増強
JP2023040219A (ja) 眼疾患の遺伝子治療
WO2017144080A1 (en) Gene therapy for the treatment of a disease of retinal cone cells
JP2023543125A (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
JP2023539247A (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用
US20170137480A1 (en) Rpgr-ofr15 variant gene in the treatment of retinitis pigmentosa
JP2022523050A5 (cg-RX-API-DMAC7.html)
CN117947041A (zh) 编码重组补体因子h多肽的核酸分子及用途